Speaker Profile

President, Trapelo Health

Biography
Clynt Taylor brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies. He joined Trapelo Health in 2017 as Chief Executive Officer and under his leadership the company developed the company’s signature product, Trapelo, which helps speed access to the most appropriate treatments for cancer patients. Since beginning his career at IBM, he’s held leadership roles at healthcare technology companies like NextGen, where he led sales and marketing teams; HealthVision as General Manager of its fastest growing division (purchased by Lawson) and Galvanon as Co-founder and CEO Healthcare Solutions (purchased by NCR). Most recently, he held various senior executive roles with NantHealth – including leading the innovation, launch and commercialization of eviti, Inc., recognized today as one of the nation’s premier oncology decision support solutions.


Clinical Dx Showcase:
Trapelo Health

Trapelo Health is a health technology company on a mission to address the challenges that result from rapid changes in the science, technology and business of next-generation cancer care. Its product, Trapelo, is a win-win solution for doctors, labs and payers that need real-time, evidence-based information and full transparency to make patient-based decisions faster. As part of this commitment, Trapelo founded The Precision Medicine Podcast.

Collaborative Precision Medicine Platform Accelerates Biomarker Adoption
The lag in biomarker adoption is preventing patients from accessing life-extending precision therapies and trials. Learn about the only collaborative, decision-support platform that aligns oncologists, labs and payers, streamlines ordering and ensures the right biomarkers are tested every time.

 Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative